Form 4: CervoMed Director David Quigley Granted Stock Options
Insider Transaction Report
CervoMed Inc. Director David Quigley was granted 16,200 stock options at an exercise price of $7.02, vesting over 36 months.
Summary
- David Quigley, a Director of CervoMed Inc. (CRVO), was granted 16,200 stock options.
- The options have an exercise price of $7.02 per share.
- The transaction date for this grant was October 27, 2025.
- The options were granted pursuant to the Issuer's 2025 Equity Incentive Plan.
- This grant is in connection with Mr. Quigley's appointment to the company's board of directors.
- The award vests in equal monthly installments over thirty-six (36) months, commencing October 31, 2025.
- The options become exercisable on October 27, 2025, and expire on October 27, 2035.
- Following this transaction, Mr. Quigley beneficially owns 16,200 derivative securities directly.
Sentiment
Score: 6
Explanation: The filing reports a standard equity grant to a director, which is a neutral to slightly positive event as it aligns interests, but does not provide new financial performance data.
Positives
- The grant of stock options to Director David Quigley aligns his financial interests with those of the shareholders, incentivizing long-term company performance.
- The use of the 2025 Equity Incentive Plan demonstrates a structured approach to executive and director compensation.
Future Outlook
The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted options.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across industries to align management and director incentives with shareholder value.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | NA | David Quigley | Prior to 10/27/2025 | Appointment to the board of directors, which led to the equity grant. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | Grant of 16,200 stock options to Director David Quigley under the company's 2025 Equity Incentive Plan. | 10/27/2025 | This action demonstrates the company's use of its approved equity compensation framework to incentivize directors, aligning their long-term interests with shareholder value, while also introducing potential future share dilution upon exercise. |
Related Party Transactions
- Grant of 16,200 stock options to David Quigley, a Director, under the company's 2025 Equity Incentive Plan.
Stakeholder Impact
- Shareholders: Potential future dilution upon the exercise of these options, but also improved alignment of the director's long-term interests with shareholder value.
- Employees: The existence and utilization of the 2025 Equity Incentive Plan may signal a broader strategy for equity compensation, potentially impacting employee retention and motivation if similar grants are extended to other personnel.
Next Steps
- The stock options will vest in equal monthly installments over 36 months, commencing October 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 10/27/2025 | Date of earliest transaction, date exercisable for stock options. |
| 10/31/2025 | Commencement of monthly vesting for the stock option award. |
| 12/05/2025 | Signature date of the filing by attorney-in-fact. |
| 10/27/2035 | Expiration date of the stock options. |
Keywords
CervoMed, CRVO, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.